Evaluation of the effects of empagliflozin on acute lung injury in rat intestinal ischemia-reperfusion model

Basit Öğe Kaydı
dc.authoridOnder, Cagatay Emir/0000-0002-0293-2309
dc.authoridVaran Koc, Gonul/0000-0002-8512-4816
dc.contributor.authorGokbulut, P.
dc.contributor.authorKuskonmaz, S. M.
dc.contributor.authorKoc, G.
dc.contributor.authorOnder, C. E.
dc.contributor.authorYumusak, N.
dc.contributor.authorErel, O.
dc.contributor.authorNural, A. S.
dc.date.accessioned2024-11-07T13:34:18Z
dc.date.available2024-11-07T13:34:18Z
dc.date.issued2023
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractBackground Empagliflozin is a selective sodium-glucose co-transporter (SGLT2) inhibitor that is approved for the treatment of type 2 diabetes. The beneficial effects of empagliflozin on other organ systems including the heart and kidneys have been proven. The aim of this study is to evaluate the role of empagliflozin on acute lung injury induced by intestinal ischemia-reperfusion (I/R). Materials and methods A total of 27 male Wistar albino rats were divided into three groups: sham, I/R, and I/R+empagliflozin; each group containing nine animals. Sham group rats underwent laparotomy without I/R injury. Rats in the I/R group underwent laparotomy, 1 h of after ischemia-reperfusion injury (superior mesenteric artery ligation was followed by 2 h of reperfusion). Rats in I/R were given empagliflozin (30 mg/kg) by gastric gavage for 7 days before the ischemia-reperfusion injury. All animals were killed at the end of reperfusion and lung tissue samples were obtained for immunohistochemical staining and histopathological investigation in all groups. Results Serum glucose, AST, ALT, creatinine, native thiol, total thiol, and disulfide levels and disulfide-native thiol, disulfide-total thiol, and native thiol-total thiol ratios as well as the IMA levels were analyzed and compared among the groups. While intestinal I/R significantly increases serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and creatinine levels; did not cause any change in homeostasis parameters and IMA level. Empagliflozin treatment had no significant effect on biochemical parameters. Empagliflozin treatment induced a significant decrease in positive immunostaining for IL-1, IL-6, TNF-alpha, caspase 3, caspase 8, and caspase 9 compared to the I/R group in lung tissue samples. Intestinal I/R caused severe histopathological injury including edema, hemorrhage, increased thickness of the alveolar wall, and infiltration of inflammatory cells into alveolar spaces. Empagliflozin treatment significantly attenuated the severity of intestinal I/R injury. Conclusions It was concluded that empagliflozin treatment may have beneficial effects in acute lung injury, and, therefore, has the potential for clinical use.
dc.identifier.doi10.1007/s40618-022-01978-1
dc.identifier.endpage1026
dc.identifier.issn0391-4097
dc.identifier.issn1720-8386
dc.identifier.issue5
dc.identifier.pmid36495440
dc.identifier.scopus2-s2.0-85143633901
dc.identifier.scopusqualityQ2
dc.identifier.startpage1017
dc.identifier.urihttps://doi.org/10.1007/s40618-022-01978-1
dc.identifier.urihttps://hdl.handle.net/11480/15910
dc.identifier.volume46
dc.identifier.wosWOS:000897335700002
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofJournal of Endocrinological Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241106
dc.subjectEmpagliflozin
dc.subjectIntestinal ischemia-reperfusion
dc.subjectAcute lung injury
dc.subjectAnti-inflammatory
dc.titleEvaluation of the effects of empagliflozin on acute lung injury in rat intestinal ischemia-reperfusion model
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu